Abstract
In this work, a co-infection model for human papillomavirus (HPV) and Chlamydia trachomatis with cost-effectiveness optimal control analysis is developed and analyzed. The disease-free equilibrium of the co-infection model is shown not to be globally asymptotically stable, when the associated reproduction number is less unity. It is proven that the model undergoes the phenomenon of backward bifurcation when the associated reproduction number is less than unity. It is also shown that HPV re-infection (εp ≠ 0) induced the phenomenon of backward bifurcation. Numerical simulations of the optimal control model showed that: (i) focusing on HPV intervention strategy alone (HPV prevention and screening), in the absence of Chlamydia trachomatis control, leads to a positive population level impact on the total number of individuals singly infected with Chlamydia trachomatis, (ii) Concentrating on Chlamydia trachomatis intervention controls alone (Chlamydia trachomatis prevention and treatment), in the absence of HPV intervention strategies, a positive population level impact is observed on the total number of individuals singly infected with HPV. Moreover, the strategy that combines and implements HPV and Chlamydia trachomatis prevention controls is the most cost-effective of all the control strategies in combating the co-infections of HPV and Chlamydia trachomatis.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
http://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Federal University of Technology Owerri, Nigeria
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm
http://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm
